CTOs on the Move

All's Well Health Care Services

www.allswell.net

 
All's Well Health Care Services is a Huntington Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.allswell.net
  • 16371 Beach Blvd Ste 141
    Huntington Beach, CA USA 92647
  • Phone: 714.596.2902

Executives

Name Title Contact Details

Similar Companies

Siskin Hospital for Physical Rehabilitation

Siskin Hospital was founded in 1989 as the first freestanding, not-for-profit rehabilitation hospital in Tennessee built specifically for rehabilitation patients. Currently, Siskin Hospital remains as the only not-for-profit rehabilitation hospital in Tennessee, offering an all-inclusive campus, as well as off-campus locations, dedicated to meeting a wide variety of rehabilitation needs. Siskin Hospital offers all private patient rooms and has specialized Inpatient treatment programs in brain injury, amputation, stroke, spinal cord injury, orthopedics, neurological disorders, and major multiple trauma, among other illnesses and disorders.

SonarMed

SonarMed is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LiteCure

LiteCure is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marlow Manor Assisted Living

Marlow Manor Assisted Living is a Anchorage, AK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Furiex

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.